Related Experiment Video
Updated: Apr 30, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
[The adverse effects of anticholinergic drugs]
Hirotaka Iwaki1, Masahiro Nomoto
1Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine.
Abstract:
Acetylcholine is one of the main neurotransmitters. It is involved in autonomic activities of the peripheral organs and forms a part of complicated neural networks in the central nervous system. Anticholinergic drugs are used in the treatment of various diseases, and many drugs have anticholinergic side effects. Thus, estimating the total burden of anticholinergic activity of drugs is important to assess the related adverse effects for patients taking such drugs. Serum anticholinergic activity (SAA) is measured using a competitive radioreceptor binding assay of muscarinic receptors. In addition to this direct measurement, several drug scales like the Anticholinergic Drug Scale (ADS), Anticholinergic Cognitive Burden Scale (ACB), and Anticholinergic Risk Scale (ARS) have been developed to estimate the total anticholinergic burden of drugs. These measurements have been used to demonstrate that certain drugs may be responsible for the cognitive impairment in the elderly or certain groups of patients with neurologic disorders. Clinicians should be aware of the impact of such drugs because central adverse effects are often obscure in these patient groups and are easily overlooked.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Related Concept Videos
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...